HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Enforcement Priorities: Eye Products, Dual Drug/Cosmetic Firms

This article was originally published in The Rose Sheet

Executive Summary

When FDA inspects a facility producing both drugs and cosmetics, the manufacturer should be using one standard and that’s the drug standard, says Karyn Campbell, director of the investigations branch at FDA’s Philadelphia District Office.


Related Content

FDA Warns Foreign Personal-Care Firms For Monograph, GMP Violations
Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012
FDA Flags Chinese Personal-Care Firm For Drug GMP Failings
Rash Of FDA Warning Letters Raises Questions For Cosmetics Industry
Unilever Hit With Suit For Negligent Marketing, Recall Of Hair Smoother
FDA Office of Regulatory Affairs Make-Over Blends Domestic, International Work
FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?
In Brief


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts